Share on LinkedInShare on LinkedIn

ARTICLE · 04 MAY 2023

Parkinson's Patent Invalid Based On Obviousness Of Overlapping Ranges

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In UCB, Inc. v. Actavis Laboratories UT, Inc., No. 2021-1924 (Fed. Cir. Apr. 12, 2023), the Federal Circuit affirmed a District of Delaware decision of invalidity based on obviousness.

United StatesIntellectual Property

In UCB, Inc. v. Actavis Laboratories UT, Inc., No. 2021-1924 (Fed. Cir. Apr. 12, 2023), the Federal Circuit affirmed a District of Delaware decision of invalidity based on obviousness.

The patent-in-suit, U.S. Patent No. 10,130,589 ("the '589 patent"), is directed to transdermal patches, for treating Parkinson's disease, containing rotigotine and a polyvinylpyrrolidone (PVP) stabilizer in a weight ratio ranging from "about 9:4 to 9:6." The district court found that other UCB patents ("the Muller patents") that are prior art to the '589 patent disclosed rotigotine:PVP ratios ranging from 9:1.5 to 9:5, which overlap with the claimed range. As a result, the district court found that the asserted claims were anticipated and rendered obvious by the Muller patents.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from